Peregrine Capital Management’s Cytokinetics CYTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.24M | Buy |
158,528
+2,791
| +2% | +$92.2K | 0.16% | 192 |
|
|
2025
Q1 | $6.26M | Buy |
155,737
+5,394
| +4% | +$217K | 0.21% | 144 |
|
|
2024
Q4 | $7.07M | Buy |
150,343
+9,432
| +7% | +$444K | 0.21% | 135 |
|
|
2024
Q3 | $7.44M | Buy |
140,911
+310
| +0.2% | +$16.4K | 0.22% | 118 |
|
|
2024
Q2 | $7.62M | Buy |
140,601
+14,208
| +11% | +$770K | 0.22% | 141 |
|
|
2024
Q1 | $8.86M | Sell |
126,393
-5,121
| -4% | -$359K | 0.25% | 105 |
|
|
2023
Q4 | $11M | Sell |
131,514
-73,150
| -36% | -$6.11M | 0.33% | 60 |
|
|
2023
Q3 | $6.03M | Buy |
204,664
+23,936
| +13% | +$705K | 0.18% | 219 |
|
|
2023
Q2 | $5.9M | Sell |
180,728
-18,688
| -9% | -$610K | 0.16% | 232 |
|
|
2023
Q1 | $7.02M | Buy |
199,416
+39,273
| +25% | +$1.38M | 0.2% | 216 |
|
|
2022
Q4 | $7.34M | Buy |
160,143
+11,309
| +8% | +$518K | 0.23% | 202 |
|
|
2022
Q3 | $7.21M | Sell |
148,834
-25,659
| -15% | -$1.24M | 0.23% | 200 |
|
|
2022
Q2 | $6.86M | Sell |
174,493
-45,047
| -21% | -$1.77M | 0.21% | 217 |
|
|
2022
Q1 | $8.08M | Buy |
219,540
+3,160
| +1% | +$116K | 0.19% | 217 |
|
|
2021
Q4 | $9.86M | Sell |
216,380
-72,116
| -25% | -$3.29M | 0.2% | 203 |
|
|
2021
Q3 | $10.3M | Sell |
288,496
-135,679
| -32% | -$4.85M | 0.21% | 205 |
|
|
2021
Q2 | $8.39M | Sell |
424,175
-22,379
| -5% | -$443K | 0.15% | 246 |
|
|
2021
Q1 | $10.4M | Sell |
446,554
-109,130
| -20% | -$2.54M | 0.19% | 228 |
|
|
2020
Q4 | $11.5M | Buy |
+555,684
| New | +$11.5M | 0.22% | 214 |
|